Prader-Willi Syndrome Market to Expand by 2036 as New Therapeutic Opportunities Address Unmet Clinical Needs | DelveInsight

Summary

DelveInsight report discusses the expected expansion of the Prader-Willi syndrome market through 2036, driven by increased disease awareness, improved diagnosis, and development of novel targeted therapies from multiple biotech companies including WAKIX, ARD-101, PBF-999, and CSTI-500.